表紙
市場調査レポート

Actavis plcの製品パイプライン分析

Actavis plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321943
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Actavis plcの製品パイプライン分析 Actavis plc - Product Pipeline Review - 2015
出版日: 2015年05月20日 ページ情報: 英文 101 Pages
概要

Actavis plc はアイルランドに本社を持つファーマシューティカル企業であり、ブランド医薬品、ジェネリック、バイオシミラー製品の開発、製造、販売を行っています。2012年にWatson pharmaceuticalsを買収した後、同社は世界60カ国以上で業務を行う世界第3位のファーマシューティカル企業として、中枢神経系、泌尿器、女性医療、ホルモン、腫瘍、心血管系、腎臓系、消化器系などの分野に対する製品を提供しています。

当レポートでは、Actavis plc における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Actavis plc の基本情報

  • Actavis plc の概要
  • 主要情報
  • 企業情報

Actavis plc :R&Dの概要

  • 主な治療範囲

Actavis plc :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Actavis plc :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 出願が却下された/取り下げられた製品/併用療法モダリティ
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA Filed Products/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Actavis plc :薬剤プロファイル

  • (ceftazidime + avibactam)
  • (memantine hydrochloride ER + donepezil hydrochloride)
  • APT-1026
  • dalbavancin
  • (nebivolol + valsartan)
  • cariprazine
  • norethindrone
  • (aclidinium bromide + formoterol fumarate)
  • estradiol acetate
  • follitropin alfa
  • pancrelipase DR
  • udenafil
  • ulipristal acetate
  • WC-2055
  • (ceftaroline fosamil + avibactam)
  • (estrogen + progesterone)
  • albaconazole
  • cebranopadol
  • memantine hydrochloride
  • oxybutynin hydrochloride
  • sarecycline
  • EUR-1100
  • Progesterone Vaginal Gel Second Generation
  • bezafibrate ER

Actavis plc :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Actavis plc :最新のパイプライン情報

Actavis plc :開発休止中のプロジェクト

Actavis plc :開発が中止された製品

Actavis plc :企業理念

Actavis plc :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07051CDB

Summary

Global Markets Direct's, 'Actavis plc - Product Pipeline Review - 2015', provides an overview of the Actavis plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actavis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Actavis plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Actavis plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Actavis plc's pipeline products

Reasons to buy

  • Evaluate Actavis plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Actavis plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Actavis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Actavis plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actavis plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Actavis plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Actavis plc Snapshot
    • Actavis plc Overview
    • Key Information
    • Key Facts
  • Actavis plc - Research and Development Overview
      Key Therapeutic Areas
  • Actavis plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Actavis plc - Pipeline Products Glance
    • Actavis plc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Actavis plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Actavis plc - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Actavis plc - Drug Profiles
    • APT-1026
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cariprazine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • norethindrone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (aclidinium bromide + formoterol fumarate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftazidime + avibactam sodium)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalbavancin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • follitropin alfa (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxin A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pancrelipase DR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarecycline hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ulipristal acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WC-3011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftaroline fosamil + avibactam sodium)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • memantine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxybutynin chloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EUR-1100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-232411
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Progesterone Second Generation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bezafibrate ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Actavis plc - Pipeline Analysis
    • Actavis plc - Pipeline Products by Target
    • Actavis plc - Pipeline Products by Route of Administration
    • Actavis plc - Pipeline Products by Molecule Type
    • Actavis plc - Pipeline Products by Mechanism of Action
  • Actavis plc - Recent Pipeline Updates
  • Actavis plc - Dormant Projects
  • Actavis plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alvameline maleate
      • dexamethasone
      • dexloxiglumide
      • ME-1036
      • neramexane mesylate
      • oglemilast
      • onabotulinumtoxin A
      • radiprodil
  • Actavis plc - Company Statement
  • Actavis plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Actavis plc, Key Information
  • Actavis plc, Key Facts
  • Actavis plc - Pipeline by Indication, 2015
  • Actavis plc - Pipeline by Stage of Development, 2015
  • Actavis plc - Monotherapy Products in Pipeline, 2015
  • Actavis plc - Combination Treatment Modalities in Pipeline, 2015
  • Actavis plc - Partnered Products in Pipeline, 2015
  • Actavis plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Actavis plc - Pre-Registration, 2015
  • Actavis plc - Filing rejected/Withdrawn, 2015
  • Actavis plc - Phase III, 2015
  • Actavis plc - Phase II, 2015
  • Actavis plc - Phase I, 2015
  • Actavis plc - IND/CTA Filed, 2015
  • Actavis plc - Discovery, 2015
  • Actavis plc - Pipeline by Target, 2015
  • Actavis plc - Pipeline by Route of Administration, 2015
  • Actavis plc - Pipeline by Molecule Type, 2015
  • Actavis plc - Pipeline Products by Mechanism of Action, 2015
  • Actavis plc - Recent Pipeline Updates, 2015
  • Actavis plc - Dormant Developmental Projects,2015
  • Actavis plc - Discontinued Pipeline Products, 2015
  • Actavis plc, Subsidiaries

List of Figures

  • Actavis plc - Pipeline by Top 10 Indication, 2015
  • Actavis plc - Pipeline by Stage of Development, 2015
  • Actavis plc - Monotherapy Products in Pipeline, 2015
  • Actavis plc - Combination Treatment Modalities in Pipeline, 2015
  • Actavis plc - Partnered Products in Pipeline, 2015
  • Actavis plc - Pipeline by Top 10 Target, 2015
  • Actavis plc - Pipeline by Top 10 Route of Administration, 2015
  • Actavis plc - Pipeline by Top 10 Molecule Type, 2015
  • Actavis plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top